Literature DB >> 27012687

The BSRBR-RA at 15 years.

Elaine M Dennison1,2, Jon Packham3, Kimme Hyrich4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27012687      PMCID： PMC5061081          DOI： 10.1093/rheumatology/kew053

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  8 in total

1.  Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  K L Hyrich; K D Watson; A J Silman; D P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2006-05-16       Impact factor: 7.580

2.  Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K D Watson; M Lunt; L K Mercer; K L Hyrich; D P M Symmons
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

3.  Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.

Authors:  Kimme L Hyrich; Kath D Watson; Mark Lunt; Deborah P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2010-07-29       Impact factor: 7.580

4.  Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.

Authors:  James B Galloway; Kimme L Hyrich; Louise K Mercer; William G Dixon; Bo Fu; Andrew P Ustianowski; Kath D Watson; Mark Lunt; Deborah P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2010-07-31       Impact factor: 7.580

5.  Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Authors:  Louise K Mercer; Mark Lunt; Audrey L S Low; William G Dixon; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2014-03-31       Impact factor: 19.103

6.  Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.

Authors:  Kimme L Hyrich; Chris Deighton; Kath D Watson; Deborah P M Symmons; Mark Lunt
Journal:  Rheumatology (Oxford)       Date:  2009-08-25       Impact factor: 7.580

7.  The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.

Authors:  Louise K Mercer; Adele C Green; James B Galloway; Rebecca Davies; Mark Lunt; William G Dixon; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2012-01-12       Impact factor: 19.103

8.  Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

Authors:  K L Hyrich; M Lunt; W G Dixon; K D Watson; D P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2008-04-17       Impact factor: 7.580
  8 in total
  6 in total

Review 1.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

2.  Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.

Authors:  Irina A Tikhonova; Huiqin Yang; Segun Bello; Andrew Salmon; Sophie Robinson; Mohsen Rezaei Hemami; Sophie Dodman; Andriy Kharechko; Richard C Haigh; Meghna Jani; Timothy J McDonald; Martin Hoyle
Journal:  Health Technol Assess       Date:  2021-02       Impact factor: 4.014

3.  The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register.

Authors:  Gareth T Jones; Gary J Macfarlane; Karen Forrest Keenan; Paul McNamee; Aileen R Neilson; Stefan Siebert; A David Burden; Lesley Kay; Philip S Helliwell
Journal:  BMC Rheumatol       Date:  2021-05-17

Review 4.  The value of pragmatic and observational studies in health care and public health.

Authors:  Maxwell S Barnish; Steve Turner
Journal:  Pragmat Obs Res       Date:  2017-05-12

5.  OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.

Authors:  Ruth Dobson; Matthew Craner; Ed Waddingham; Aleisha Miller; Ana Cavey; Stewart Webb; Cheryl Hemingway; Jeremy Hobart; Nikos Evangelou; Neil Scolding; David Rog; Richard Nicholas; Monica Marta; Camilla Blain; Carolyn Anne Young; Helen L Ford; Paul M Matthews
Journal:  BMJ Open       Date:  2021-11-25       Impact factor: 2.692

6.  Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventions.

Authors:  Michael Seo; Thomas Pa Debray; Yann Ruffieux; Sandro Gsteiger; Sylwia Bujkiewicz; Axel Finckh; Matthias Egger; Orestis Efthimiou
Journal:  Stat Methods Med Res       Date:  2022-04-26       Impact factor: 2.494
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.